# A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

> **NCT04735575** · PHASE1,PHASE2 · TERMINATED · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** EMB-06

## Key facts

- **NCT ID:** NCT04735575
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-20
- **Primary completion:** 2024-08-20
- **Final completion:** 2024-08-20
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Company's resource optimization and product's development change
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735575, "A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04735575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*